FORTITUDE-ALS

Update on results of Phase 2
10 May, 2019


Results from the Phase 2 clinical trial of FORTITUDE-ALS have recently been made available. The full press release from the American Academy of Neurology is available here. The trial failed to meet either of its primary or secondary endpoints, with the trial finding the following:
  • no statistical significance demonstrated for change in slow vital capacity (SVC) from baseline following 12 weeks of dosing; and
  • dose-response analyses for the secondary endpoint failed to demonstrate statistical significance between reldesemtiv and the placebo arms.
However, data did reveal that all patients who received reldesemtiv declined less for both SVC and ALSFRS-R (revised Amyotrophic Lateral Sclerosis Functional Rating Scale), when compared to those taking the placebo.
 
A spokesperson from Cytokinetics said: “While FORTITUDE-ALS did not meet the primary endpoint, we are encouraged by the results of the trial as they further validate the potential of skeletal muscle activation in treating patients battling ALS … This Phase II trial of reldesemtiv demonstrated consistency of effect for doses, endpoints, and time points and we believe the results support progression of reldesemtiv in further clinical trials toward potential registration.”
 
Cytokinetics have recently uploaded a webcast that discusses the results of the trial in further detail. 
 
 

Proud member of:

International Alliance of ALS/MND Associations

ACNC Registered Charity

 

MND Australia would like to advise Aboriginal and Torres Strait Islander users that this website may contain images or names of deceased persons.